如何利用CD19 CAR T细胞成功或失败的风险因素指导儿童及青少年B细胞急性淋巴细胞白血病的管理
本文综述儿童、青少年及年轻成人复发/难治性B细胞急性淋巴细胞白血病接受CD19 CAR T细胞治疗的文献,梳理患者特异性风险因素,并介绍作者团队的管理路径。文章讨论何时应考虑巩固性造血细胞移植或实验性CAR T细胞及替代免疫治疗,并提出需要前瞻性试验的领域。
要点
- 10%至30%的患者未达到缓解,超过半数最终复发。
- 已有两种独特CD19 CAR T细胞构建体商业化上市用于B-ALL。
- 作者提出需前瞻性试验探讨CAR T细胞治疗的最佳使用。
核心结论
- CD19 CAR T细胞可使化疗耐药患者获得深度完全缓解并可能长期治愈,但10%至30%未达缓解且超过半数最终复发。
- 作者认为患者特异性风险因素可指导巩固性造血细胞移植或实验性CAR T细胞及替代免疫治疗的选择。
研究设计与样本
- 综述类文章,汇总前瞻性研究及近期大型回顾性研究,结合作者团队管理经验,并纳入两种商业化CD19 CAR T细胞构建体数据。
主要发现
- 10%至30%的患者未达到缓解,超过半数接受治疗的患者最终复发。
- 已有两种独特CD19 CAR T细胞构建体商业化上市用于B-ALL。
关键数值与推荐
- 文章汇总了前瞻性及近期大型回顾性研究中关于CAR T细胞治疗失败风险高低的数据。
- 文章提出可考虑巩固性造血细胞移植或实验性CAR T细胞及替代免疫治疗的时机观点。
临床怎么用
- 作者介绍了基于患者个体因素优化CD19 CAR T细胞治疗结局的策略。
- 作者提出需前瞻性试验探讨CAR T细胞治疗的最佳使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
By overcoming chemotherapeutic resistance, chimeric antigen receptor (CAR) T cells facilitate deep, complete remissions and offer the potential for long-term cure in a substantial fraction of patients with chemotherapy refractory disease. However, that success is tempered with 10% to 30% of patients not achieving remission and over half of patients treated eventually experiencing relapse. With over a decade of experience using CAR T cells in children, adolescents, and young adults (AYA) to treat relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and 5 years since the first US Food and Drug Administration approval, data defining the nuances of patient-specific risk factors are emerging. With the commercial availability of 2 unique CD19 CAR T-cell constructs for B-ALL, in this article, we review the current literature, outline our approach to patients, and discuss how individual factors inform strategies to optimize outcomes in children and AYA receiving CD19 CAR T cells. We include data from both prospective and recent large retrospective studies that offer insight into understanding when the risks of CAR T-cell therapy failure are high and offer perspectives suggesting when consolidative hematopoietic cell transplantation or experimental CAR T-cell and/or alternative immunotherapy should be considered. We also propose areas where prospective trials addressing the optimal use of CAR T-cell therapy are needed.
引用
- Myers RM, Shah NN, Pulsipher MA, et al. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. Blood. 2023. PMID: 36416729. doi:10.1182/blood.2022016937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。